2. Academic Validation
  3. Xihuang pill suppressed primary liver cancer growth by downregulation of AFP and YAP signaling

Xihuang pill suppressed primary liver cancer growth by downregulation of AFP and YAP signaling

  • J Ethnopharmacol. 2025 May 28:348:119891. doi: 10.1016/j.jep.2025.119891.
Sha Luo 1,  Zhen Huang 2,  Yuewen Dai 3,  Shuyang Wang 4,  Wantao Yu 5,  Zhihan Li 6,  Qing Pu 7,  Lihui Yang 8,  Tianyi Yang 9,  Yu Tang 10,  Zhang Wang 11,  Jiabo Wang 12,  Jingxiao Wang 13
Affiliations

Affiliations

  • 1 College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China. Electronic address: shashas777@outlook.com.
  • 2 Department of Hepatobiliary Surgery, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: zhen.huang@cicams.ac.cn.
  • 3 Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, China. Electronic address: 934725814@qq.com.
  • 4 School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China. Electronic address: shungsss@outlook.com.
  • 5 School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China. Electronic address: yuwantao998@163.com.
  • 6 School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China. Electronic address: c070161@qq.com.
  • 7 School of Traditional Chinese Medicine, Capital Medical University, Beijing, China. Electronic address: jaexlgg@163.com.
  • 8 Oncology Department, The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital), Xi'an, China. Electronic address: 863407484@qq.com.
  • 9 School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China. Electronic address: Yty1650584972@163.com.
  • 10 Center of Pharmaceutical Technology, Tsinghua University, Beijing, China. Electronic address: tangyu@tsinghua.edu.cn.
  • 11 College of Ethnomedicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China; State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, China. Electronic address: wangzhangcqcd@cdutcm.edu.cn.
  • 12 College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China; School of Traditional Chinese Medicine, Capital Medical University, Beijing, China; State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Beijing, China. Electronic address: jiabo_wang@ccmu.edu.cn.
  • 13 School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China; Capital Medical University Research and Translational Laboratory for Traditional Chinese Medicine in the Prevention and Treatment of Infectious Severe Hepatitis, Beijing, China. Electronic address: 201801022@bucm.edu.cn.
PMID: 40294663 DOI: 10.1016/j.jep.2025.119891
Abstract

Ethnopharmacological relevance: Xihuang Pill (XHP) is a traditional Chinese medicine formula that was originally used to treat malignant ulcers. Recent studies revealed its therapeutic effects on various malignant tumors. However, its potential efficacy and mechanisms in primary liver Cancer (PLC) were not thoroughly investigated.

Aim of the study: This study aimed to elucidate the efficacy and potential mechanisms of XHP in the treatment of PLC.

Methods: An orthotopic PLC mice model was established adopting hydrodynamic tail vein injection method. Human liver Cancer cell lines and organoids were utilized to assess the effect of XHP in vitro. The expressions of alpha-fetoprotein (AFP) and Yes-associated protein (YAP) were evaluated with western blotting. The mRNA expressions of YAP downstream targets were detected with qRT-PCR. Data from Liver Hepatocellular Carcinoma Collection of the Cancer Genome Atlas (TCGA-LIHC) were extracted to identify the potential targets of HCC. The major active components of XHP methanol extract and XHP medicated serum were detected by UHPLC-MS/MS. Human liver Cancer cell lines were used to assess the efficacy and potential mechanisms of these active components in XHP in vitro. Finally, molecular docking was conducted to predict the binding affinities of XHP's active components with AFP and YAP.

Results: XHP inhibited PLC tumor growth in the mice model with decreased AFP and Ki-67 index. In vitro, XHP suppressed the proliferation and migration of liver Cancer cell lines in a time- and dose-dependent manner. Furthermore, even with a low concentration (5 mg/mL), XHP paralyzed the growth of PLC organoids derived from patients. Mechanistically, XHP downregulated the expression of AFP and YAP signaling in vitro and in vivo. UHPLC-MS/MS analysis identified 25 active components in XHP medicated serum. Among them, certain active compounds suppressed PLC cell proliferation and downregulated AFP and YAP signaling, suggesting their therapeutic potentials in PLC. Molecular docking indicated that several components in XHP exhibited strong binding affinities with both AFP and YAP.

Conclusion: XHP inhibited PLC growth by suppressing AFP and YAP signaling. This study provides an experimental basis for XHP application in PLC treatment.

Keywords

AFP; Primary liver cancer; Traditional Chinese medicine; Xihuang pill; YAP signaling.

Figures
Products